SCHEMBL15057089

SCHEMBL15057089

CC(C)COc1ccc(Cl)c(Cn2ncc3cc(C(=O)O)ccc32)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLA2G4A P47712 2/20 0.44
▸ MAOA P21397 1/20 0.41
▸ MAOB P27338 1/20 0.41
▸ NR1H4 Q96RI1 4/20 0.40
▸ SLC16A3 O15427 1/20 0.39
▸ SLC16A1 P53985 1/20 0.39
▸ MCTS1 Q9ULC4 1/20 0.39
▸ ESR2 Q92731 1/20 0.39
▸ ALOX5AP P20292 1/20 0.38
▸ PPARG P37231 1/20 0.38
▸ KMO O15229 1/20 0.37
▸ RARA P10276 1/20 0.37
▸ RARB P10826 1/20 0.37
▸ RARG P13631 1/20 0.37
▸ GCK P35557 1/20 0.37
▸ ITGB3 P05106 1/20 0.36
▸ ITGAV P06756 1/20 0.36
▸ ITGA2B P08514 1/20 0.36
▸ KDM4A O75164 1/20 0.36
▸ KDM5A P29375 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15057111 0.90 MAOA (0.44) PLA2G4AMAOAMAOBSLC16A3SLC16A1
SCHEMBL15057169 0.88 PLA2G4A (0.44) PLA2G4ANR1H4PPARGRARARARB
SCHEMBL15057589 0.87 PLA2G4A (0.42) PLA2G4ANR1H4
SCHEMBL15056932 0.86 EPHX2 (0.44) PLA2G4ANR1H4PPARG
SCHEMBL15057731 0.85 KDM4A (0.42) PLA2G4AMAOAMAOBKMOKDM4A
SCHEMBL15057625 0.83 PLA2G4A (0.45) PLA2G4ANR1H4SLC16A3SLC16A1PPARG
SCHEMBL15076165 0.82 PTGER1 (0.53) —
SCHEMBL15057775 0.82 PLA2G4A (0.43) PLA2G4ANR1H4
SCHEMBL20629004 0.81 PLA2G4A (0.42) PLA2G4A
SCHEMBL15057237 0.81 RORC (0.42) PLA2G4APPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3424904-B1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2020-12-02 — — EP claimed
EP-3424904-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE Allergan, Inc. (US) 2019-01-09 — — EP claimed
EP-2794561-B1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2018-08-22 — — EP claimed
US-9567328-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2017-02-14 — — US claimed
EP-2794561-A2 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2014-10-29 — — EP claimed
US-20130184463-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-07-18 — — US claimed
WO-2013096496-A2 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-06-27 — — WO claimed
US-20210221810-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. 2021-07-22 — — US disclosed
US-10988474-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2021-04-27 — — US disclosed
EP-3424904-B1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2020-12-02 — — EP disclosed
US-20200216440-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2020-07-09 — — US disclosed
US-10392382-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2019-08-27 — — US disclosed
EP-3424904-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE Allergan, Inc. (US) 2019-01-09 — — EP disclosed
EP-2794561-B1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2018-08-22 — — EP disclosed
US-20170137423-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2017-05-18 — — US disclosed
US-9567328-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2017-02-14 — — US disclosed
EP-2794561-A2 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2014-10-29 — — EP disclosed
US-20130184463-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-07-18 — — US disclosed
WO-2013096496-A2 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200216440-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER2 PLA2G4A 181/4885MAOA 3577/4885MAOB 3900/4885
US-20210221810-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER2 PLA2G4A 181/4885MAOA 3577/4885MAOB 3900/4885
US-10392382-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response PTGER1, PTGER4, PTGER2 PLA2G4A 181/4885MAOA 3577/4885MAOB 3900/4885
US-10988474-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response PTGER1, PTGER4, PTGER2 PLA2G4A 181/4885MAOA 3577/4885MAOB 3900/4885
US-20130184463-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER2 PLA2G4A 181/4885MAOA 3577/4885MAOB 3900/4885
US-20170137423-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER2 PLA2G4A 181/4885MAOA 3577/4885MAOB 3900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback